Search: id:"swepub:oai:DiVA.org:liu-52911" >
Expression of FXYD3...
Expression of FXYD3 Protein in Relation to Biological and Clinicopathological Variables in Colorectal Cancers
-
- Widegren, Emma (author)
- Linköpings universitet,Institutionen för klinisk och experimentell medicin,Hälsouniversitetet,Linkoping Univ, Dept Oncol, Inst Clin & Expt Med, SE-58185 Linkoping, Sweden
-
- Önnesjö, Sofia (author)
- Linköpings universitet,Institutionen för klinisk och experimentell medicin,Hälsouniversitetet,Linkoping Univ, Dept Oncol, Inst Clin & Expt Med, SE-58185 Linkoping, Sweden
-
- Arbman, Gunnar (author)
- Östergötlands Läns Landsting,Kirurgiska kliniken i Östergötland med verksamhet i Linköping, Norrköping och Motala,Landstinget i Östergötland,Vrinnevi Univ Hosp, Dept Surg, Norrkoping, Sweden
-
show more...
-
- Kayed, Hany (author)
- Univ Heidelberg, Inst Clin Radiol and Nucl Med, Univ Hosp Mannheim, Heidelberg, Germany
-
- Zentgraf, Hanswalter (author)
- German Canc Res Ctr, D-6900 Heidelberg, Germany
-
- Kleeff, Joerg (author)
- Tech Univ Munich, Dept Surg, Munich, Germany
-
- Zhang, Hong (author)
- Högskolan i Skövde,Institutionen för vård och natur,Univ Skovde, Sch Life Sci, Skovde, Sweden
-
- Sun, Xiao-Feng (author)
- Östergötlands Läns Landsting,Linköpings universitet,Onkologi,Hälsouniversitetet,Onkologiska kliniken US,Linkoping Univ, Dept Oncol, Inst Clin & Expt Med, SE-58185 Linkoping, Sweden
-
show less...
-
(creator_code:org_t)
- 2009-12-02
- 2009
- English.
-
In: Chemotherapy. - : S. Karger AG. - 0009-3157 .- 1421-9794. ; 55:6, s. 407-413
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
show less...
Abstract
Subject headings
Close
- Background: FXYD3 is up-/down-regulated in different types of cancers. We examined FXYD3 expression in colorectal cancers and its relationship to biological and clinicopathological variables. Patients and Methods: Expression of FXYD3 protein was immunohistochemically examined in distant normal mucosa (n = 34), adjacent normal mucosa (n = 72), primary tumour (n = 150) and lymph node metastasis (n = 35) from colorectal cancer patients. Results: FXYD3 was highly expressed in primary tumour compared to adjacent normal mucosa (p = 0.02). FXYD3 was or tended to be positively related to the expression of ras (p = 0.02), p53 (p = 0.06), legumain (p = 0.02) and proliferating cell nuclear antigen (p = 0.03). Moreover, there was a higher frequency of strong FXYD3 expression in Dukes A-C tumours than in D tumours (p = 0.04). The strong FXYD3 expression tended to predict worse survival in the patients with Dukes A + B tumour (p = 0.07), while there was no such tendency in the patients with Dukes C + D tumour (p = 0.94). The tumours located in the colon had a higher degree of FXYD3 expression than the tumours located in the rectum (p = 0.05). Conclusion: The FXYD3 was associated with certain biological variables and may be involved in the development of the relative earlier stages of colorectal cancers.
Keyword
- Colorectal cancer; FXYD3; Immunohistochemistry
- MEDICINE
- MEDICIN
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database